The New York Genome Center is focused on furthering genomic research that leads to scientific advances and new insights and therapies for patients with neurodegenerative disease, neuropsychiatric disease, and cancer, leveraging our strengths in whole genome sequencing, genomic analysis, and development of genomic tools.

We have established programs in each of these areas, and consider the exchange of ideas among researchers, both within and outside the center, to be essential for the development of new genomic technologies, the advancement of basic science, and the understanding of the genetic basis of human diseases. Five affiliate working groups have been established: Neurodegenerative Disease, Neuropsychiatric Disease, Computational Cancer Genomics, Population Genomics, and Enabling Innovation. These new working groups, along with our founding working group, the Genome Center Cancer Group, are forums for discussing current research advances, technical and conceptional challenges to further progress, and the establishment of joint projects and funding strategies.

Neurodegenerative disease (ALS, Alzheimer’s, Parkinson’s, Huntington’s): Leveraging the success of our Center for Genomics of Neurodegenerative Disease’s focus on ALS research to extend our work across a range of neurodegenerative diseases that share common pathways with ALS.

Neuropsychiatric disease (autism, schizophrenia, bipolar): Broadening our robust research of whole genomes of autism patients through our common disease NIH center grant focused on autism to expand into other neuropsychiatric disorders, including schizophrenia and bipolar disorder.

Cancer: Pushing forward the leading edge of cancer genomics research through our glioblastoma study, Cancer Alliance, and the new Polyethnic-1000 project and by focusing on whole genome sequencing of individuals with cancer and their tumors, novel population-level cancer analytics, and the application of both single cell and spatial transcriptomics.

Technology InnovationFurther developing successful collaborative initiatives in single cell and spatial transcriptomics and the computational methods necessary to understand the underlying biology and disease mechanisms.

Population Genomics: Focusing on human population genomics, statistical analyses, and applications to precision medicine.